4.8 Article

Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 168, Issue 3, Pages 271-279

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2013.03.025

Keywords

Bioreducible nanogel; Vaccine adjuvant; Antigen presentation; Antibody production; Cytotoxic T-lymphocyte response

Funding

  1. National Natural Science Foundation of China [81171446]
  2. Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies (GIRTF-LCHT)
  3. Science and Technology Program of Guangdong Province [2012B090400043, 2012B090600036]
  4. Shenzhen Science and Technology Program [JC201005260247A]
  5. Chinese Academy of Sciences

Ask authors/readers for more resources

Although polysaccharide nanogels have emerged as a novel antigen delivery system for vaccine development, whether modulating the redox sensitivity of nanogels could improve vaccine efficacy remains unclear. In the present study, we generated bioreducible cationic alginate-polyethylenimine (PEI) nanogels as a novel vaccine delivery system. Briefly, nanogels were prepared by the electrostatic interaction of negatively charged alginate sodium with branched PEI2k, followed by disulfide cross-linking to generate bioreducible nanogels (AP-SS). The AP-SS nanogels demonstrated great antigen-loading capacity and minimal cytotoxicity. The in vitro study showed that reducible AP-SS nanogels not only facilitated antigen uptake by mouse bone marrow dendritic cells (BMDCs), but also promoted intracellular antigen degradation and cytosolic release. Moreover, AP-SS nanogels significantly enhanced both MHC class I and II antigen presentation by BMDCs. Compared with the non-reducible nanogels, AP-SS nanogels more potently enhanced vaccine-induced antibody production and CD8(+) T cell-mediated tumor cell lysis. Hence, the bioreducible alginate-PEI nanogels could serve as a potent adjuvant to improve vaccine-elicited humoral and cellular immune responses. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available